Close Menu

NEW YORK (GenomeWeb) – Veracyte said after the close of the market on Tuesday that it is planning a public offering of 5 million shares of its common stock.

The molecular diagnostics firm will also grant underwriters a 30-day option to purchase up to 750,000 additional shares.

Veracyte said it plans to use the net proceeds for working capital and other corporate purposes, and that it may also use some of the proceeds to acquire or invest in complementary businesses or technologies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.

Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.

The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.

In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.

Dec
03
Sponsored by
Mission Bio

Recent work by many investigators has discovered that over the course of aging, hematopoietic stem cells (HSCs) commonly undergo clonal expansion.